Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies

Andrea Poletti, Stafano Delle Vedove, Gaia Mazzocchetti, Vincenza Solli, Ajsi Kanapari, Enrica Borsi, Marina Martello, Giovanni Martinelli, Silvia Armuzzi, Ilaria Vigliotta, Barbara Taurisano, Ignazia Pistis, Elena Zamagni, Michele Cavo, Carolina Terragna

Blood (2022) 140 (Supplement 1): 1559–1560.

https://doi.org/10.1182/blood-2022-164822

Published: 2022

Journal Articles

Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients

Alice Bettelli, MS, Rita Ruggiano, Silvia Bocchi, Laura Rocchi, PhD, Andrea Faenza, PhD, Enrica Borsi, Carolina Terragna, Elena Zamagni, MD, Marina Martello, Marco Bettelli, Laura Rambelli, Viviana Guadagnuolo, Nicola Pecorari, Luca Giulianelli, Matteo Pisani, Dario Biscarini, Michele Cavo, Roberto Guerrieri, Massimo Bocchi, PhD

Blood (2019) 134 (Supplement_1): 3372.

https://doi.org/10.1182/blood-2019-126894

Published: 2019

Journal Articles

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Bachisio Ziccheddu, PhD, Giulia Biancon, Chiara De Philippis, MD, Filippo Bagnoli, MD, Francesco Maura, MD, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, PhD, Eftathios Kastritis, Meletios A. Dimopoulos, MD, Michele Cavo, Cristiana Carniti, PhD, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli, MD PhD

Blood (2019) 134 (Supplement_1): 3056.

https://doi.org/10.1182/blood-2019-122197

Published: 2019

Journal Articles

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1778.

https://doi.org/10.1182/blood-2019-127799

Published: 2019

Journal Articles

A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis

Blood (2019) 134 (Supplement_1): 1797.

https://doi.org/10.1182/blood-2019-129975

Published: 2019

Journal Articles

Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients: An Analysis of the Prospective Randomized EMN02/HO95 Study

Blood (2017) 130 (Supplement 1): 4545.

https://doi.org/10.1182/blood.V130.Suppl_1.4545.4545

Published: 2017

Journal Articles

Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006

Erik H Van Beers, Carolina Terragna, Marina Martello, Elena Zamagni, MD, Michele Cavo, MD, Martin H van Vliet, PhD, Giovanni Martinelli, MD, Rowan Kuiper, MSc

Blood (2017) 130 (Supplement 1): 4358.

https://doi.org/10.1182/blood.V130.Suppl_1.4358.4358

Published: 2017

Journal Articles

Definition of a Prognostic Risk-Classifier Based on SNPs Array Analysis of Copy Number Alterations in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 3053.

https://doi.org/10.1182/blood.V130.Suppl_1.3053.3053

Published: 2017

Journal Articles

The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 1769.

https://doi.org/10.1182/blood.V130.Suppl_1.1769.1769

Published: 2017

Journal Articles

A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs

Carolina Terragna, Marina Martello, Barbara Santacroce, Vincenza Solli, Lucia Pantani, Elena Zamagni, Paola Tacchetti, Beatrice Anna Zannetti, Katia Mancuso, Giulia Marzocchi, Nicoletta Testoni, Gaia Ameli, Rosalinda Termini, Flores A Dico, Enrica Borsi, Giovanni Martinelli, Michele Cavo

Blood (2016) 128 (22): 2080.

https://doi.org/10.1182/blood.V128.22.2080.2080

Published: 2016

Journal Articles

An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival

Carolina Terragna, PhD, Marina Martello, PhD, Mauro Procacci, Flavio Mignone, Annalisa Pezzi, PhD, Barbara Santacroce, Lucia Pantani, MD, Igor Saggese, Torsten Haferlach, Elena Zamagni, Enrica Borsi, PhD, Paola Tacchetti, MD, Beatrice A Zannetti, MD, Serena Rocchi, MD, Katia Mancuso, MD, Flores A Dico, Giovanni Martinelli, MD PhD, Michele Cavo

Blood (2015) 126 (23): 24.

https://doi.org/10.1182/blood.V126.23.24.24

Published: 2015

Journal Articles

The Alternate Activation of Hedgehog Pathway, Either in CD138+ or in CD138-CD19+ Multiple Myeloma Primary Cells, Impacts on Disease Outcome

Marina Martello, PhD, Daniel Remondini, PhD, Enrica Borsi, PhD, Mauro Procacci, Barbara Santacroce, Annalisa Pezzi, PhD, Angela Flores Dico, Elena Zamagni, Paola Tacchetti, MD, Lucia Pantani, MD, Giulia Marzocchi, PhD, Giovanni Martinelli, MD PhD, Michele Cavo, Carolina Terragna, PhD

Blood (2015) 126 (23): 2961.

https://doi.org/10.1182/blood.V126.23.2961.2961

Published: 2015

Journal Articles

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

Blood (2014) 124 (21): 3400.

https://doi.org/10.1182/blood.V124.21.3400.3400

Published: 2014

Journal Articles

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Marina Martello, PhD, Angela Flores Dico, Daniel Remondini, PhD, Giovanni Martinelli, MD, Enrica Borsi, PhD, Barbara Santacroce, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Anna Beatrice Zannetti, MD, Katia Mancuso, MD, Serena Rocchi, MD, Annalisa Pezzi, Statistician, Nicoletta Testoni, PhD, Giulia Marzocchi, PhD, Gaia Ameli, Michele Cavo, MD, Carolina Terragna, PhD

Blood (2014) 124 (21): 2054.

https://doi.org/10.1182/blood.V124.21.2054.2054

Published: 2014

Journal Articles

Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial

Blood (2014) 124 (21): 2033.

https://doi.org/10.1182/blood.V124.21.2033.2033

Published: 2014

Journal Articles

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Carolina Terragna, PhD, Marina Martello, Enrica Borsi, PhD, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Brioli Annamaria, MD, Beatrice Anna Zannetti, MD, Flores Dico, Nicoletta Testoni, BS, Giulia Marzocchi, PhD, Katia Mancuso, MD, Serena Rocchi, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1855.

https://doi.org/10.1182/blood.V122.21.1855.1855

Published: 2013

Journal Articles

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

Blood (2012) 120 (21): 1810.

https://doi.org/10.1182/blood.V120.21.1810.1810

Published: 2012

Journal Articles

SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma

Enrica Borsi, Giulia Perrone, MD, Carolina Terragna, PhD, Marina Martello, Manuela Mancini, PhD, Elisa Leo, PhD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2012) 120 (21): 574.

https://doi.org/10.1182/blood.V120.21.574.574

Published: 2012

Journal Articles

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

Carolina Terragna, PhD, Marina Martello, Sandra Durante, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Giulia Perrone, MD, Beatrice Anna Zannetti, MD, Enrica Borsi, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2011) 118 (21): 3935.

https://doi.org/10.1182/blood.V118.21.3935.3935

Published: 2011

Journal Articles

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 805.

https://doi.org/10.1182/blood.V118.21.805.805

Published: 2011

NARROW

A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies

Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis

Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients: An Analysis of the Prospective Randomized EMN02/HO95 Study

Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006

Definition of a Prognostic Risk-Classifier Based on SNPs Array Analysis of Copy Number Alterations in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients

The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients

A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs

An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival

The Alternate Activation of Hedgehog Pathway, Either in CD138+ or in CD138-CD19+ Multiple Myeloma Primary Cells, Impacts on Disease Outcome

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only